Investors love dividend stocks because they provide dependable passive income streams and an excellent opportunity for solid ...

Here are three dividend stocks that retirees can buy with confidence as they offer recurring, dependable payouts and a degree ...

Earlier patent litigation can be reformed to reflect similar success across Europe, resulting in accelerated US biosimilar ...

The pharma expects a modest financial headwind this year from changes to Medicare prescription drug benefits under the ...

Organon has faced significant price volatility and underperformance since its spin-off from Merck. Check out why I recommend ...

AbbVie (NYSE:ABBV) has managed to keep its market share for its bestselling arthritis therapy, Humira, above 70%, generic ...

With the expiry of multiple biologic patents fast approaching, there is a huge opportunity for the NHS to make further ...

Amgen's biosimilar ambition is targeting several ... especially while its shares remain down. Pfizer's dividend is safer than it looks David Jagielski(Pfizer): A high-yielding stock that could ...

High-yield dividend stocks may not appeal to some investors. However, if you're among those investors looking for income, ...

South Korean biosimilars developer Samsung Bioepis and Israel’s Teva Pharmaceutical Industries have entered into a license, development and commercialization agreement for Epysqli (eculizumab-aagh), ...